Laquinimod
- Catalog NO.:A847230
- CAS No. : 248281-84-7
- Molecular Formula:C19H17ClN2O3
- Molecular Weight: 356.8
1. Please click the to confirm the discount and stock quantity.
2. Click“Bulk Inquiry”to ask for quotations of other quantity.
3. The price does not include shipping and bank charges.
Product Details
CAS Number | 248281-84-7 | Appearance | |
Catalog Number | A847230 | MDL Number | MFCD08689859 |
Molecular Formula | C19H17ClN2O3 | Molecular Weight | 356.8 |
Boiling Point | Melting Point | ||
Flash Point | Density | ||
Synonyms | ABR-215062;5-Chloro-4-hydroxy-1-methyl-2-oxo-N-ethyl-N-phenyl-1,2-dihydroquinoline-3-carboxamide | ||
Storage Condition | Store in a tightly closed container,in a cool and dry place |
Safety
GHS Pictogram | |||
Signal Word | Warning | UN Number | |
Hazard Statements | H302-H315-H319-H332-H335 | Class | |
Precautionary Statements | P261-P280-P305+P351+P338 | Packing Group |
Description
Laquinimod, also known as, is an experimental immunomodulator developed by Active Biotech and Teva. It is being investigated as an oral treatment for multiple sclerosis (MS). Laquinimod is the successor of Active Biotech's failed experimental immunomodulator linomide. Laquinimod seems to be able to reduce the MS disease activity on MRI. In 2011, Teva announced its clinical trials involving laquinimod had failed, being unable to significantly reduce relapses into MS among patients beyond a placebo. However, the final results of above-mentioned phase III trial proved oral laquinimod administered once daily slowed the progression of disability and reduced the rate of relapse in patients with relapsing–remitting multiple sclerosis. |